STOCK TITAN
  1. Home
  2. News
  3. ADAP

Adaptimmune Therapeutics Plc - ADAP STOCK NEWS

Welcome to our dedicated news page for Adaptimmune Therapeutics Plc (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adaptimmune Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adaptimmune Therapeutics Plc's position in the market.

News
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) terminates strategic collaboration with Genentech, remains focused on launching afami-cel with a PDUFA date of August 4th and developing its sarcoma franchise. Update on launch plans to be provided at the April 18th Investor Day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.08%
Tags
none
-
News
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Rhea-AI Summary
Adaptimmune Therapeutics plc (ADAP) announces the publication of pivotal Phase 2 data with afami-cel in The Lancet, showcasing promising results in treating advanced synovial sarcoma and myxoid/round cell liposarcoma. The study demonstrates a 39% overall response rate in synovial sarcoma, indicating potential life extension and reduced chemotherapy dependence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
Rhea-AI Summary
Adaptimmune Therapeutics plc reported the U.S. FDA accepting BLA for afami-cel for advanced synovial sarcoma treatment with a priority review and a PDUFA date of August 4th, 2024. The company aims to launch afami-cel upon FDA approval with a sales projection of up to $400 million. The sarcoma franchise includes afami-cel and lete-cel, targeting synovial sarcoma and MRCLS patients. Financially, the company has a cash runway into early 2026 with over $300 million in cash. Clinical pipeline updates show promising results for ADP-A2M4CD8 in various solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.12%
Tags
earnings
News
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Rhea-AI Summary
Adaptimmune reappoints Cintia Piccina as Chief Commercial Officer to lead the launch of afami-cel for advanced synovial sarcoma treatment. The company aims to leverage her expertise in cell therapy and commercialization as they prepare for the product's market entry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
management earnings
-
News
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Rhea-AI Summary
Adaptimmune Therapeutics plc (ADAP) to report financial results and business updates for Q4 and full year 2023, with a live webcast scheduled on March 6, 2024. Investors can access the press release and webcast details on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
conferences
-
News
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
Rhea-AI Summary
Adaptimmune Therapeutics plc announced that the U.S. FDA has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. If approved, it will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in over a decade. The Prescription Drug User Fee Act (PDUFA) target action date is August 4, 2024. Clinical trials have shown an impressive response rate of ~39% among heavily pre-treated patients with advanced synovial sarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
clinical trial
News
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) announced plans for its emerging sarcoma franchise, projecting peak US sales of up to $400 million. The company aims to launch afami-cel in the US in 2024 and lete-cel in 2026. The pivotal trial for lete-cel met its primary endpoint for efficacy, and the company is funded into early 2026 with over $300 million, including existing balance sheet and projected payments from partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.33%
Tags
none
-
News
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) submits the first BLA for afami-cel, an engineered T-cell therapy for synovial sarcoma, to the FDA. Positive data from the pivotal trial SPEARHEAD-1 show better outcomes compared to historical control data. The submission is supported by the completion of the rolling BLA, making afami-cel eligible for Priority Review, potentially shortening the FDA's review timeline. The company is preparing for the commercial launch of afami-cel and the evolution of its sarcoma cell therapy franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
News
Adaptimmune Receives Transfer of IND for Lete-cel Program
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) announces the transfer of the IND for letetresgene autoluecel (lete-cel) from GSK to Adaptimmune for the pivotal IGNYTE-ESO (NCT03967223) clinical trial. The interim analysis of the pivotal IGNYTE-ESO trial demonstrates a 40% response rate in people with synovial sarcoma or myxoid/round cell liposarcoma. The company plans to lay out its cell therapy sarcoma franchise, including afami-cel and lete-cel, in January 2024. Adaptimmune and GSK have agreed terms regarding the return of the NY-ESO program back to Adaptimmune, resulting in milestone-based payments totaling £30 million in relation to the transfer of the clinical trials for the NY-ESO targeted programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
none
News
Adaptimmune Reports Third Quarter Financial Results and Business Update
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP): Afami-cel's BLA submission on track for Q4 completion, showing superior survival rates for synovial sarcoma patients. SURPASS Phase 1 trial reports 75% response rate in ovarian, urothelial, and head & neck cancers. Pipeline update includes termination of Gavo-cel and TC-510 programs. Financially, the company's cash runway is confirmed into early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
earnings
Stock ADAP logo
Adaptimmune Therapeutics Plc

Nasdaq:ADAP

ADAP Rankings

#3562 Ranked by Market Cap
#4938 Ranked by Stock Gains
N/A Ranked by Dividends

ADAP Stock Data

263.23M
734.09M
0.2%
67.52%
1.3%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
Abingdon

About ADAP

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.